

Accelerating global development with an Asian oncology platform

ASLAN Pharmaceuticals is a clinical-stage oncology and immunology focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe

Developing in Asia for global markets

- Strategically positioned in Asia with access to larger patient population where target cancers are prevalent
- Development platform in Asia enables acceleration of drug development and generation of data suitable for submission to regulators in US, Europe and Japan
- Few, if any, approved therapies in biliary tract cancer
- Experienced global management team with deep local relationships and extensive knowledge of target diseases
- Building commercial organisation in China and planning to build in US

Quick facts

Ticker

- NASDAQ: ASLN
- TPEX: 6497

(Each US ADS equivalent to 5 TPEX common shares)

Shares outstanding

160,248,940

Market Cap

US\$130M

(26 March 2019, NASDAQ)

Cash

US\$22M

(31 March 2019)

Varlitinib (ASLAN001)

Potential to be the first targeted therapy approved for biliary tract cancer

- Highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2, HER3 and HER4
- Demonstrated activity in biliary tract, gastric, breast and colorectal cancer. Two phase 2 trials completed, over 600 patients dosed
- Low levels of toxicity compared to other pan-HER inhibitors
- Competitive efficacy with 60% response rate demonstrated in second line HER2+ breast cancer
- Currently no approved targeted therapies for biliary tract cancer which affects more than 200,000 people in Asia every year
- Received Orphan Drug Designation from the US FDA for biliary tract cancer
- Biliary tract cancer: pivotal TreeTopp trial enrolment completed in early 2019, topline data expected in 2H 19

ASLAN003

Oral DHODH inhibitor with potential to be first-in-class therapy for acute myeloid leukaemia (AML)

- Potent inhibition of DHODH, binding affinity up to two orders of magnitude stronger than first generation inhibitors
- Promotes differentiation of blast cells in multiple cell lines that are unresponsive to ATRA
- Lack of toxicities associated with first generation inhibitors and other AML therapies
- Received Orphan Drug Designation from the US FDA for AML
- Interim data from phase 2 trial in relapsed or refractory AML patients showed early signs of clinical activity in lower dose cohorts, and data was presented at ASH 2018
- Preclinical studies in triple negative breast cancer and hepatocellular carcinoma underway
- Part 1 readout 2Q 2019

ASLAN004

IL-4R / IL-13R inhibitor with the potential to be best-in-class therapy for atopic dermatitis and asthma

- Potently inhibits signaling of both IL-4 and IL-13 receptors which are central to the allergic response in atopic dermatitis and asthma
- By targeting IL-13R α 1, a receptor with a narrower cellular distribution than the IL-4 receptor, it has the potential to offer both a lower dose and lower dosing frequency than current alternatives for target indications
- Phase 1 atopic dermatitis single ascending dose study expected to complete in 1H 2019
- MAD study in moderate-to-severe atopic dermatitis patients expected to start in 2H 2019

Programs	Discovery	Preclinical	Phase 1	Phase 2	Pivotal	Key Milestones
Global rights						
Varlitinib <i>Pan-HER inhibitor</i>	Biliary tract cancer (2nd line)					Topline data 2H 19
	Biliary tract cancer (1st line)					
ASLAN003 <i>DHODH inhibitor</i>	AML					Part 1 readout 2Q 19
ASLAN004 <i>IL4R/IL13R inhibitor</i>	Atopic dermatitis					SAD completion 2Q 19
	Asthma					
Partnered programs						
ASLAN002 <i>RON/MET inhibitor</i> <i>Partnered with BMS</i>	Solid tumors					

Management

Dr Carl Firth
Chief Executive Officer

Dr Mark McHale
Chief Development Officer
and Head of R&D

Dr Chih-Yi Hsieh
Chief Medical Officer

Stephen Doyle
Chief Business Officer

Ben Goodger
General Counsel

Kiran Asarpota
VP Finance

Major partnerships



Analyst coverage

Edward Tenthoff
Piper Jaffray

Jonathan Chang
Leerink Partners

Raghuram Selvaraju
H C Wainwright & Co

Robert Hazlett
BTIG

John Chang
President Capital Management Corp

Headquarters

83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
+65 6222 4235
contact@aslanpharma.com

Investor contact (Taiwan)

Michael Chiang
ASLAN Pharmaceuticals
+886 2 2758 2767
investor-taiwan@aslanpharma.com

Investor contact

Robert Uhl
Westwicke Partners
+1 858 356 5932
robert.uhl@westwicke.com

Media contact

Emma Thompson
Spurwing Communications
+65 6340 7287
emma@spurwingcomms.com